As advised via Pharmac Tender announcement 31 August 2018 there is to be a change in the listing and future sole supply.

New listing from 1 February 2019

Aurorix Tab 150 mg 60                                        Pharmacode 2560429                  Schedule price $6.40

Aurorix Tab 300 mg 60                                        Pharmacode 2560437                              Schedule price $9.80

Incumbent brand

Moclobemide-Apo Tab 150 mg 500                 Pharmacode 2129264         Schedule price $85.10

Moclobemide-Apo Tab 300 mg 100                 Pharmacode 2129272         Schedule price $30.70

Reference pricing will apply from 1 April 2019.

HML (Hospital Supply Status) commences 1 April 2019 and CSS (Community Supply Status) commences 1 July 2019.

As of the date of this notification ProPharma / PWR cannot accept Moclobemide-Apo Tablets for credit under any circumstances.

We recommend you continue to purchase the incumbent and we will change automatically (where practical) as existing stocks are exhausted.

You simply need to manage your stock so that you have ZERO stock at time of reference pricing being 1 April 2019 unless otherwise advised.

Once again we need your support to ensure stock in the supply chain moves through, to effectively ensure no losses are incurred.

Together we can make this a seamless and painless transition.We thank you in anticipation of your ongoing support.

About The Author